Advertisement

Regression of aneurysmal type 1 neovascularization after brolucizumab injections

Published:October 01, 2021DOI:https://doi.org/10.1016/j.jcjo.2021.09.001
      A 68-year-old man presented with progressive visual acuity decline OS. Optical coherence tomography revealed an irregular pigment epithelial detachment (PED) and a ring-like lesion enclosed in a peaked PED (inlet) with intra- and subretinal fluid (A). Early-phase indocyanine green angiography showed a branching vascular network (BVN) with an aneurysmal dilation (arrowhead) at the temporal margin of the BVN (B). One month after 2 brolucizumab intravitreal injections, complete resorption of fluid, flattening of the PED, and disappearance of the aneurysmal dilation were observed (C, D), along with reduced vascular density of the BVN. Brolucizumab could have a prominent role in the management of aneurysmal type 1 neovascularization. Fig.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect